Clinical Trials Browser

NCT06378177 2026-05-19

A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC)

Phase 2 Active not recruiting

64 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT07423078 2026-04-13

WOLF

Phase 2 Recruiting

87 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis, Recurrence

NCT05635643 2026-03-19

Study of CHS-114 in Participants With Advanced Solid Tumors

Phase 1 Recruiting

87 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Neoplasms

NCT07371897 2026-01-28

SHINE

Phase 3 Not yet recruiting

154 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT07088211 2025-07-31

Sacituzumab Tirumotecan and Toripalimab in the First-line Treatment of HNSCC

Phase 2 Recruiting

39 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT06861712 2025-04-25

Chemoimmunotherapy With or Without SBRT Before Surgery for Locally Advanced Oral and Oropharyngeal Cancer

Phase 2 Not yet recruiting

50 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT06647563 2024-10-18

Neoadjuvant Toripalimab + Chemotherapy ± Cetuximab in Locally Advanced Head and Neck Squamous Cell Carcinoma (Neo-ICT)

Phase 3 Not yet recruiting

355 enrolled

Head & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck

NCT05773079 2024-04-01

Toripalimab Maintenance for Locally Advanced Head and Neck Squamous Cell Carcinoma

Phase 2 Not yet recruiting

28 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT05125055 2023-11-22

Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC

Phase 2/3 Recruiting

80 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT06081582 2023-10-13

Toripalimab in Combined With Cetuximab，Chemotherapy for Conversion Therapy of Locally Nonresectable OCSCC

Phase 2 Unknown

33 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT05993858 2023-08-15

PC-1

Phase 2 Not yet recruiting

33 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT04807140 2023-04-14

Neoadjuvant Toripalimab or Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated HNSCC (HNSCC-002)

Phase 2 Recruiting

57 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT05803915 2023-04-07

Neoadjuvant Toripalimab Plus Nimotuzumab in Oral Squamous Cell Carcinoma Prior to Radical Therapy

Phase 2 Unknown

57 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT02915432 2021-12-13

The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC

Phase 1/2 Unknown

401 enrolled 1 FDA

GastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Esophageal Squamous Cell Carcinoma

NCT04947241 2021-07-01

Toripalimab Combined With Gemcitabine and Cisplatin Treating Resectable Locally Advanced HNSCC

Phase 1 Unknown

20 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT04523883 2021-04-15

IMPORT

Phase 2 Unknown

316 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04164238 2019-11-15

Neoadjuvant Anti-PD-1 Antibody (Toripalimab) or Combined With Chemotherapy in HNSCC Patients

Phase 2 Unknown

90 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck